Converting enzyme inhibition in chronic renal failure

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hypertension is a common complication in patients with chronic renal failure.
• Triple drug therapy (propranolol-hydralazine-furosemide) effectively controlled hypertension in these patients.
• The potential benefits of angiotensin-converting enzyme (ACE) inhibitors on renal function in this population require further investigation.

Purpose of the Study:

• To evaluate the efficacy of captopril, an ACE inhibitor, in controlling hypertension in patients with chronic renal failure.
• To assess the impact of captopril on renal function, including glomerular filtration rate and tubular secretion.
• To determine if ACE inhibition can alter the progression of chronic renal failure.

Main Methods:

• Ten patients with chronic renal failure and controlled hypertension were switched from triple drug therapy to captopril.
• Hypertension control was monitored over a 12-month period.
• Renal function was assessed by measuring the clearance of inulin and paraaminohippuric acid, and by monitoring the reciprocal of serum creatinine.

Main Results:

• Hypertension control was comparable between the initial triple drug regimen and captopril therapy.
• Captopril therapy led to a significant increase in the clearance of inulin and paraaminohippuric acid within 3 months, with sustained effects.
• The decline in the reciprocal of serum creatinine, indicative of worsening renal function, was halted during captopril treatment.

Conclusions:

• ACE inhibitor therapy with captopril is effective in controlling hypertension in patients with chronic renal failure.
• Captopril demonstrates beneficial effects on renal function, improving filtration and secretion.
• ACE inhibition may represent a therapeutic strategy to slow the progression of renal failure, warranting further long-term studies.